Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 1,200 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $237.66, for a total transaction of $285,192.00. Following the transaction, the insider directly owned 142,486 shares in the company, valued at $33,863,222.76. The trade was a 0.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.

Natera Stock Down 1.9%

Shares of NTRA stock traded down $4.45 during trading hours on Thursday, hitting $231.48. 947,123 shares of the company were exchanged, compared to its average volume of 1,043,018. The firm has a fifty day moving average of $235.90 and a 200 day moving average of $193.29. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The firm has a market cap of $32.02 billion, a PE ratio of -101.08 and a beta of 1.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period last year, the company posted ($0.26) EPS. Analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NTRA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. Evercore ISI raised their price target on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Morgan Stanley lifted their price target on shares of Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. JPMorgan Chase & Co. increased their price objective on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, BNP Paribas Exane raised shares of Natera to a “hold” rating and set a $172.00 target price on the stock in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $249.20.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. D.A. Davidson & CO. purchased a new position in shares of Natera during the 4th quarter valued at approximately $570,000. Kestra Private Wealth Services LLC bought a new stake in shares of Natera in the fourth quarter worth $271,000. Pictet Asset Management Holding SA raised its holdings in Natera by 2.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 50,883 shares of the medical research company’s stock valued at $11,657,000 after acquiring an additional 1,447 shares in the last quarter. Huntleigh Advisors Inc. boosted its stake in Natera by 5.3% during the 4th quarter. Huntleigh Advisors Inc. now owns 11,412 shares of the medical research company’s stock valued at $2,614,000 after acquiring an additional 570 shares during the last quarter. Finally, UBS Group AG grew its holdings in Natera by 19.4% during the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after acquiring an additional 71,355 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.